United States
Search    
Include All CSL Behring Country Sites

CSL BEHRING SIGNS STRATEGIC DEVELOPMENT AGREEMENT WITH ENABLE INJECTIONS TO MARKET NOVEL NEW DRUG DELIVERY DEVICE

King of Prussia, Pa. — 28 October 2014

CSL Behring announced today that its affiliate company, CSL Behring AG, of Bern, Switzerland and Enable Injections, LLC, of Franklin, Ohio have signed a long-term development agreement for a new and innovative drug delivery system intended to improve the comfort, convenience and treatment compliance for patients with rare and serious diseases.

As part of the strategic global collaboration, Enable will develop, manufacture and sell its innovative treatment administration device, which was specifically designed for subcutaneous dosing, to CSL Behring for use with one of its products on an exclusive worldwide basis. CSL Behring has the option to add subsequent additional products and extend the term of the agreement for additional periods. CSL Behring and Enable have also agreed to discuss other potential subcutaneous product partnerships. Under the terms of the agreement, Enable will receive an upfront payment, as well as specific milestone payments over the next several years. Additional royalty payments are also called for throughout the course of the agreement. Further terms of the agreement were not disclosed.

"At CSL Behring, we are committed to serving patients with rare and serious diseases by providing treatments that save and extend lives," said Bob Repella, Executive Vice President, Global Commercial Operations, CSL Behring. "One of the ways we do this is by focusing on medical advancements and new technologies that address patients' needs and improve their quality of life. Through our collaboration with Enable Injections, we hope to bring patients a delivery option that makes administration of their therapy easier, helps improve treatment compliance and offers them greater freedom and flexibility to treat their condition in a way that fits their individual needs."

"People living with chronic diseases have to routinely manage their condition," said Mike Hooven, CEO of Enable Injections. "Our innovative drug delivery system makes administering a life-long treatment easier and much more convenient. We are thrilled to partner with a scientific leader like CSL Behring to, upon regulatory approvals, bring this device to patients in the rare disease community who may benefit from our innovative drug delivery system."

For more information about CSL Behring, visit www.cslbehring.com, for CSL Behring AG, http://www.cslbehring.ch/home, and for Enable Injections, LLC, www.enableinjections.com.

About Enable Injections LLC

Enable Injections is a company that has developed a platform technology to deliver high viscosity/volume payloads up to 20cc to the subcutaneous tissue. The system uses standard vial, syringe or cartridge container closure, and can automatically mix lyophilized solutions. Founded February 2010, the company has R&D and manufacturing facilities in Franklin, Ohio.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a global biopharmaceutical company and a member of the CSL Group of companies. The parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia. For more information, visit http://www.cslbehring.com.

###

Media Contacts:

Natalie de Vane
CSL Behring
Office: 610-878-4468
Mobile: 610-999-8756
Natalie.deVane@cslbehring.com
Edna Kaplan
KOGS Communications
Office: 781-639-1910
Mobile: 617-974-8659
Kaplan@kogspr.com

CRP16-05-0001 05/2016
© 2016 CSL Behring